Advertisement

Topics

New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer

13:36 EDT 17 Apr 2019 | Speciality Pharma Journal

SAN CARLOS, Calif., April 16, 2019 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), Cancer Research UK, Imperial College London and the University of Leicester, today announced the publication of results of a clinical study demonstrating that the Signatera™ research-use-only (RUO) molecular residual disease (MRD) assay detected disease relapse up to two years earlier than imaging in …

Original Article: New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Assays
An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity.  This can be a drug or biochemical substance or a cell in an organism or organic sample. ...